Novel humanized monoclonal antibodies for targeting hypoxic human tumors via two distinct extracellular domains of carbonic anhydrase IX
ConclusionCA9hu-1 and CA9hu-2 are the very first humanized antibodies against CA IX that are likely to become suitable therapies for hypoxic tumors. These antibodies can be applied in the treatment therapy of primary tumors and suppression of metastases formation. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - February 2, 2022 Category: Cancer & Oncology Source Type: research
MicroRNA-377-3p inhibits hepatocellular carcinoma growth and metastasis through negative regulation of CPT1C-mediated fatty acid oxidation
ConclusionsWe uncover the key function and the relevant mechanisms of the miR-377-3p/CPT1C axis in HCC, which might provide a potential target for the treatment of HCC. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - January 20, 2022 Category: Cancer & Oncology Source Type: research
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover
ConclusionsOverall, these studies demonstrate that androgen-independent prostate cancer cell growth can be influenced by extracellular lipid levels and LDL-cholesterol availability and that uptake of extracellular cholesterol, through endocytosis of LDL-derived cholesterol and subsequent delivery and storage in the lipid droplet as cholesteryl esters, is required to support prostate cancer cell growth. This provides new insights into the relationship between extracellular cholesterol, intracellular cholesterol metabolism, and prostate cancer cell growth and the potential mechanisms linking hypercholesterolemia and more agg...
Source: Cancer and Metabolism - January 15, 2022 Category: Cancer & Oncology Source Type: research
Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin
ConclusionsWe provided the evidence that HK1 is involved in the so far unknown glycolysis-independent HK1 –metformin axis and influences metabolism even in glucose-free conditions. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - December 11, 2021 Category: Cancer & Oncology Source Type: research
ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism
ConclusionsccRCC tumors downregulate the components of the urea cycle including the enzymes argininosuccinate synthase 1 (ASS1) and argininosuccinate lyase (ASL). These cytosolic enzymes lie at a critical metabolic hub in the cell and are involved in aspartate catabolism and arginine and nitric oxide biosynthesis. Loss of ASS1 and ASL helps cells redirect aspartate towards pyrimidine synthesis and support enhanced proliferation. Additionally, reduced levels of ASS1 and ASL might help regulate nitric oxide (NO) generation and mitigate its cytotoxic effects. Overall, our work adds to the understanding of urea cycle enzymes i...
Source: Cancer and Metabolism - December 3, 2021 Category: Cancer & Oncology Source Type: research
Dynamic regulation of mitochondrial pyruvate metabolism is necessary for orthotopic pancreatic tumor growth
ConclusionsWe found that any substitution of alanine for serine at regulatory sites generated a hypomorphic PDC. However, the reduced PDC activity was insensitive to further reduction in hypoxia. These cells had a very modest reduction of growth in vitro, but failed to grow as tumors indicating that dynamic PDC adaptation to microenvironmental conditions is necessary to support pancreatic cancer growth in vivo. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - November 8, 2021 Category: Cancer & Oncology Source Type: research
Detection of glucose-derived d- and l-lactate in cancer cells by the use of a chiral NMR shift reagent
ConclusionsThe shift-reagent-aided NMR technique demonstrates thatd-lactate is produced from glucose in NSCLC cells via the methylglyoxal pathway. The biological role ofd-lactate is uncertain but a convenient method for monitoringd-lactate production could provide new insights into the biological roles ofd- versusl-lactate in cancer metabolism. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - November 6, 2021 Category: Cancer & Oncology Source Type: research
3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation
ConclusionsOverall, MCT1-mediated metabolic perturbation in combination with radiotherapy is shown to be a promising strategy for the treatment of glycolytic tumors such as TNBC, overcoming the selectivity challenges of targeting glycolysis with glucose analogs. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - October 14, 2021 Category: Cancer & Oncology Source Type: research
Breast cancer growth and proliferation is suppressed by the mitochondrial targeted furazano[3,4-b]pyrazine BAM15
ConclusionsCollectively, these data indicate that mitochondrial uncoupling may be an effective strategy to limit proliferation of aggressive forms of breast cancer. More broadly, these findings highlight the metabolic vulnerabilities of highly proliferative breast cancers which may be leveraged in overcoming poor responsiveness to existing therapies. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - October 9, 2021 Category: Cancer & Oncology Source Type: research
mGWAS identification of six novel single nucleotide polymorphism loci with strong correlation to gastric cancer
ConclusionsOur study unveiled several novel GC metabolite and genetic biomarkers, which may be implicated in the prevention and diagnosis of gastric cancer. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - September 26, 2021 Category: Cancer & Oncology Source Type: research
Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines
ConclusionsTo facilitate the use of our transcriptional metabolic landscape, we have provided access to all data via a web portal (www.themetaboliclandscapeofcancer.com). We believe this resource will contribute to the formulation of new hypotheses on how to metabolically engage the tumor or its (immune) microenvironment. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - September 26, 2021 Category: Cancer & Oncology Source Type: research
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer
ConclusionsOur study highlights an in-depth characterization of SCLC metabolic programming and presents glycolysis as a targetable mechanism downstream of MYC that could offer therapeutic benefit in a subset of SCLC patients. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - September 23, 2021 Category: Cancer & Oncology Source Type: research
Brief report: The uricase mutation in humans increases our risk for cancer growth
ConclusionA loss of uricase increases the risk for tumor growth. Prior studies have shown that the loss of the mutation facilitated the ability of fructose to increase fat which provided a survival advantage for our ancestors that came close to extinction from starvation in the mid Miocene. Today, however, excessive fructose intake is rampant and increasing our risk not only for obesity and metabolic syndrome, but also cancer. Obesity-associated cancer may be due, in part, to a mutation 15 million years ago that acted as a thrifty gene. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - September 15, 2021 Category: Cancer & Oncology Source Type: research
Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies
ConclusionsThese studies suggest thatde novo lipogenesis may be a common survival strategy for many lymphoid malignancies and may be a clinically exploitable metabolic liability.Trial registrationThis study does not include any clinical interventions on human subjects. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - August 16, 2021 Category: Cancer & Oncology Source Type: research
Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma
ConclusionOur study demonstrates the possible molecular mechanisms underlying CCA recurrence, and these may associate with the existence of CSCs. The metabolic change involved in the recurrence pathway might be used to determine biomarkers for predicting CCA recurrence. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - August 4, 2021 Category: Cancer & Oncology Source Type: research
